solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
DANAZOL |
Dopamine Transporter |
89% |
6.842uM |
5.436uM |
View
|
arachidonate 15-lipoxygenase, second type |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
BETA-ESTRADIOL |
Lipoxygenase 15-LO |
89% |
11.295uM |
NoneNone |
View
|
nuclear receptor subfamily 3, group C, member 1 |
ETHINYLESTRADIOL |
Glucocorticoid |
89% |
1.71uM |
.777uM |
View
|
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
4-OCTYLPHENOL |
Dopamine Transporter |
89% |
8.491uM |
6.746uM |
View
|
prostaglandin-endoperoxide synthase 2 |
PHENOTHIAZINE |
Cyclooxygenase COX-2 |
89% |
.532uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
PHENOTHIAZINE |
Cyclooxygenase COX-2 |
89% |
.532uM |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
TIRILAZAD |
Calcium Channel Type L, Benzothiazepine |
89% |
2.694uM |
2.395uM |
View
|
potassium voltage-gated channel, subfamily H, member 8 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 6 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 7 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 5 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 3 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 4 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 1 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
potassium voltage-gated channel, subfamily H (eag-related), member 1 |
MITOXANTRONE |
Potassium Channel HERG |
89% |
3.5849uM |
2.937uM |
View
|
Cytochrom P450-1A2 monooxygenase |
BW-723C86 |
CYP450-1A2 Inhibition |
89% |
.8738uM |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
PERHEXILINE |
Calcium Channel Type L, Benzothiazepine |
89% |
1.0569uM |
.9394uM |
View
|
thromboxane A synthase 1 |
GRAMICIDIN |
Thromboxane Synthetase |
88% |
.774uM |
NoneNone |
View
|
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
GRAMICIDIN |
Thromboxane Synthetase |
88% |
.774uM |
NoneNone |
View
|
adrenergic receptor, alpha 2a |
METHAPYRILENE |
Adrenergic alpha2A |
88% |
1.165uM |
.437uM |
View
|
Sigma-2 Receptor |
BROMHEXINE |
Sigma2 |
88% |
.059uM |
.036uM |
View
|
arachidonate 15-lipoxygenase, second type |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
FERULIC ACID |
Lipoxygenase 15-LO |
88% |
3.975uM |
NoneNone |
View
|
histamine receptor H 2 |
BENZTROPINE |
Histamine H2 |
88% |
1.206uM |
1.185uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type III, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type I, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type II, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type X, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type IV, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type III, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type II, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type I, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type I, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type IV, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel associated protein 1 |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel associated protein 2 |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type III, beta |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
sodium channel, voltage-gated, type I, alpha |
BENZTROPINE |
Sodium Channel, Site 2 |
88% |
1.68uM |
1.533uM |
View
|
dopamine receptor D4 |
HALOPERIDOL |
Dopamine D4.2 |
87% |
.563uM |
.198uM |
View
|
adrenergic receptor, alpha 2b |
HALOPERIDOL |
Adrenergic alpha2B |
87% |
1.354uM |
.618uM |
View
|
dopamine receptor D1A |
GENTIAN VIOLET |
Dopamine D1 |
87% |
3.102uM |
1.551uM |
View
|
cholinergic receptor, muscarinic 4 |
MIANSERIN |
Muscarinic M4 |
87% |
2.066uM |
.288uM |
View
|
histamine receptor H 2 |
MIANSERIN |
Histamine H2 |
87% |
1.008uM |
.992uM |
View
|
Cytochrom P450-2D6 monooxygenase |
LYSERGOL |
CYP450-2D6 Inhibition |
87% |
1uM |
NoneNone |
View
|
dopamine receptor 2 |
METHYSERGIDE |
Dopamine D2L |
87% |
.807uM |
.269uM |
View
|
mitogen activated protein kinase 14 |
1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
87% |
.746uM |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
87% |
.746uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 |
ETODOLAC |
Cyclooxygenase COX-2 |
87% |
.561uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
ETODOLAC |
Cyclooxygenase COX-2 |
87% |
.561uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
LORATADINE |
Serotonin 5-HT2B |
86% |
.245uM |
.156uM |
View
|
mitogen activated protein kinase 14 |
1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
86% |
.537uM |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
Protein Serine/Threonine Kinase, p38alpha |
86% |
.537uM |
NoneNone |
View
|
A3 adenosine receptor |
1-NAPHTHYL ISOTHIOCYANATE |
Adenosine A3 |
86% |
6.1uM |
3.448uM |
View
|
acetylcholinesterase (YT blood group) |
IRINOTECAN |
Acetylcholinesterase |
86% |
1.827uM |
NoneNone |
View
|
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
IRINOTECAN |
Acetylcholinesterase |
86% |
1.827uM |
NoneNone |
View
|
acetylcholinesterase |
IRINOTECAN |
Acetylcholinesterase |
86% |
1.827uM |
NoneNone |
View
|
dopamine receptor D1A |
KETOTIFEN |
Dopamine D1 |
86% |
.872uM |
.436uM |
View
|
opioid receptor, kappa 1 |
SAQUINAVIR |
Opiate kappa |
86% |
6.951uM |
2.78uM |
View
|
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
RITONAVIR |
CYP450-2C9 Inhibition |
86% |
.016uM |
NoneNone |
View
|
cytochrome P450, family 2, subfamily C, polypeptide 9 |
RITONAVIR |
CYP450-2C9 Inhibition |
86% |
.016uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 3a |
OLANZAPINE |
Serotonin 5-HT3 |
86% |
1.316uM |
.296uM |
View
|
5-hydroxytryptamine (serotonin) receptor 3b |
OLANZAPINE |
Serotonin 5-HT3 |
86% |
1.316uM |
.296uM |
View
|
sodium channel, voltage-gated, type IV, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel associated protein 1 |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel associated protein 2 |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type III, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type I, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type III, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type I, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type II, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type X, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type IV, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type III, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type II, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type I, beta |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
sodium channel, voltage-gated, type I, alpha |
ORPHENADRINE |
Sodium Channel, Site 2 |
86% |
2.492uM |
2.274uM |
View
|
Cytochrom P450-2D6 monooxygenase |
BUPIVACAINE HYDROCHLORIDE |
CYP450-2D6 Inhibition |
86% |
.4uM |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
U-78517F |
Calcium Channel Type L, Dihydropyridine |
86% |
1.659uM |
1.066uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
TAMOXIFEN |
Calcium Channel Type L, Dihydropyridine |
85% |
8.585uM |
5.519uM |
View
|
Cytochrom P450-1A2 monooxygenase |
NIFEDIPINE |
CYP450-1A2 Inhibition |
85% |
.3uM |
NoneNone |
View
|
adrenergic receptor, alpha 2a |
ERGONOVINE |
Adrenergic alpha2A |
85% |
1.68uM |
.63uM |
View
|
dopamine receptor 2 |
ERGONOVINE |
Dopamine D2L |
85% |
.552uM |
.184uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
CISAPRIDE |
Calcium Channel Type L, Benzothiazepine |
85% |
.802uM |
.713uM |
View
|
adrenergic receptor, alpha 2b |
CISAPRIDE |
Adrenergic alpha2C |
85% |
.78uM |
.113uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
CISAPRIDE |
Adrenergic alpha2C |
85% |
.78uM |
.113uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2C |
ATROPINE |
Serotonin 5-HT2C |
85% |
1.012uM |
.53uM |
View
|
Sigma-2 Receptor |
CLEMASTINE |
Sigma2 |
85% |
.728uM |
.448uM |
View
|
adrenergic receptor, alpha 2a |
CLOZAPINE |
Imidazoline I2, Central |
85% |
.384uM |
.256uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
CLOZAPINE |
Imidazoline I2, Central |
85% |
.384uM |
.256uM |
View
|
Protein-tyrosine kinase, Fyn |
S(-)-CARBIDOPA |
Protein Tyrosine Kinase, Fyn |
85% |
3.731uM |
NoneNone |
View
|
opioid receptor, sigma 1 |
MOSAPRIDE |
Sigma1 |
85% |
.3056uM |
.1284uM |
View
|
dopamine receptor D3 |
MEPAZINE |
Dopamine D3 |
85% |
2.006uM |
.681uM |
View
|
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
2-ACETYLAMINOFLUORENE |
Serotonin Transporter |
85% |
6.053uM |
3.216uM |
View
|
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
CYP450-2C9 Inhibition |
85% |
2uM |
NoneNone |
View
|
cytochrome P450, family 2, subfamily C, polypeptide 9 |
1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE |
CYP450-2C9 Inhibition |
85% |
2uM |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type III, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type II, beta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type I, beta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PUROMYCIN |
Sodium Channel, Site 2 |
12% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type IV, beta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel associated protein 1 |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel associated protein 2 |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type III, beta |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type I, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
MEPAZINE |
Sodium Channel, Site 2 |
85% |
2.521uM |
2.3uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type X, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type IV, beta |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type III, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type II, beta |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type I, beta |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type IV, beta |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel associated protein 1 |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel associated protein 2 |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type III, beta |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PAROXETINE |
Sodium Channel, Site 2 |
85% |
2.69uM |
2.454uM |
View
|
Sigma-2 Receptor |
PROCHLORPERAZINE |
Sigma2 |
85% |
.676uM |
.416uM |
View
|